Area of research
Oncology · Immunology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses, and Immune Cell Function and Interaction.
MITF regulates IDH1, NNT, and a transcriptional program protecting melanoma from reactive oxygen species
Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti–PD-1 therapy
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Precise T cell recognition programs designed by transcriptionally linking multiple receptors
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade
Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
PAK4 inhibition improves PD-1 blockade immunotherapy
Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress
Genetic Mechanisms of Immune Evasion in Colorectal Cancer
Immunotherapy Resistance by Inflammation-Induced Dedifferentiation
A Pilot Trial of the Combination of Transgenic NY-ESO-1–reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab
Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance
Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells